UK markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
133.66+3.03 (+2.32%)
At close: 04:00PM EDT
130.63 -3.03 (-2.27%)
Pre-market: 08:00AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 12.63B
Enterprise value 12.62B
Trailing P/E 310.84
Forward P/E 40.82
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.06
Price/book (mrq)13.14
Enterprise value/revenue 8.99
Enterprise value/EBITDA 131.83

Trading information

Stock price history

Beta (5Y monthly) 0.95
52-week change 33.01%
S&P500 52-week change 322.38%
52-week high 3159.89
52-week low 355.25
50-day moving average 3125.80
200-day moving average 3112.07

Share statistics

Avg vol (3-month) 3872.3k
Avg vol (10-day) 31.21M
Shares outstanding 594.52M
Implied shares outstanding 694.52M
Float 890.36M
% held by insiders 14.39%
% held by institutions 187.01%
Shares short (15 Apr 2024) 44.87M
Short ratio (15 Apr 2024) 47.68
Short % of float (15 Apr 2024) 45.39%
Short % of shares outstanding (15 Apr 2024) 45.16%
Shares short (prior month 15 Mar 2024) 44.97M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:6
Last split date 312 Jul 2012

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 1.20%
Operating margin (ttm)8.44%

Management effectiveness

Return on assets (ttm)-1.89%
Return on equity (ttm)2.02%

Income statement

Revenue (ttm)1.4B
Revenue per share (ttm)14.95
Quarterly revenue growth (yoy)63.10%
Gross profit (ttm)N/A
EBITDA -52.99M
Net income avi to common (ttm)16.9M
Diluted EPS (ttm)0.43
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.39B
Total cash per share (mrq)14.71
Total debt (mrq)1.4B
Total debt/equity (mrq)145.20%
Current ratio (mrq)4.05
Book value per share (mrq)10.17

Cash flow statement

Operating cash flow (ttm)-533.67M
Levered free cash flow (ttm)-366.59M